These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22436635)

  • 1. [Use of drug-eluting stents: impact of French recommendations on the rate of clinical restenosis at 2 years].
    Mboup MC; Moquet B; Zabalawi A; Delaunay R
    Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):88-92. PubMed ID: 22436635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden.
    James SK; Stenestrand U; Lindbäck J; Carlsson J; Scherstén F; Nilsson T; Wallentin L; Lagerqvist B;
    N Engl J Med; 2009 May; 360(19):1933-45. PubMed ID: 19420363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients.
    Xu B; Li JJ; Yang YJ; Ma WH; Chen JL; Qiao SB; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2006 Apr; 119(7):533-8. PubMed ID: 16620692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug-eluting stents: do we respect the on-label use in our daily practice?].
    Puymirat E; Chaib A; Chaudeurge A; Trinquart L; Ledru F; Durand E; Danchin N; Blanchard D
    Ann Cardiol Angeiol (Paris); 2010 Aug; 59(4):196-204. PubMed ID: 20708171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-stent restenosis: the gold standard has changed.
    Chin K
    EuroIntervention; 2011 May; 7 Suppl K():K43-6. PubMed ID: 22027726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
    Stone GW; Lansky AJ; Pocock SJ; Gersh BJ; Dangas G; Wong SC; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Ochala A; Kellock A; Parise H; Mehran R;
    N Engl J Med; 2009 May; 360(19):1946-59. PubMed ID: 19420364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.
    Yeh RW; Normand SL; Wolf RE; Jones PG; Ho KK; Cohen DJ; Cutlip DE; Mauri L; Kugelmass AD; Amin AP; Spertus JA
    Circulation; 2011 Oct; 124(14):1557-64. PubMed ID: 21900079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
    Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Sarno G; Lagerqvist B; Fröbert O; Nilsson J; Olivecrona G; Omerovic E; Saleh N; Venetzanos D; James S
    Eur Heart J; 2012 Mar; 33(5):606-13. PubMed ID: 22232428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Abukaresh R; Aurigemma C; De Luca L; Zavalloni D; Soregaroli D; Marino P; Garbo R; Zanolla L; Vassanelli C;
    Am J Med; 2011 May; 124(5):434-43. PubMed ID: 21531233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study.
    Rittger H; Brachmann J; Sinha AM; Waliszewski M; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Breithardt OA; Schmidt M; Zimmermann S; Lonke S; von Cranach M; Nguyen TV; Daniel WG; Wöhrle J
    J Am Coll Cardiol; 2012 Apr; 59(15):1377-82. PubMed ID: 22386286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings.
    Aoki J; Kirtane AJ; Dangas GD; Lansky AJ; Morales A; Kimura M; Kim YH; Moussa I; Weisz G; Kreps EM; Collins M; Frankin-Bond T; Stone GW; Moses JW; Leon MB; Mehran R
    Am J Cardiol; 2008 Jan; 101(1):58-62. PubMed ID: 18157966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.